News

Filter

Current filters:

Vectibix

1 to 9 of 57 results

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

Amgen trials show no differences in quality of life between the FOLFOX regimens with or without Vectibix

16-01-2015

USA-based Amgen, the world’s leading independent biotech firm, says that Phase II and Phase III studies…

AmgenBiotechnologyOncologyResearchVectibix

Amgen’s Vectibix approved for colorectal cancer by FDA

Amgen’s Vectibix approved for colorectal cancer by FDA

27-05-2014

USA-based Amgen, the world's leading independent biotech firm, has announced that the US Food and Drug…

AmgenBiotechnologyChemotherapy regimensMetastatic colorectal cancerOncologyRegulationUSAVectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

1 to 9 of 57 results

Back to top